Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing

Toxicological Sciences

Volumn 142, Issue 1, 2014, Pages 210-224

  Wetmore, Barbara A ^a   Allen, Brittany ^a   Clewell, Harvey J ^a   Parker, Timothy ^a   Wambaugh, John F ^b   Almond, Lisa M ^c   Sochaski, Mark A ^a   Thomas, Russell S ^a,b  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

Dosimetry; In vitro in vivo extrapolation; Population variability; Reaction phenotyping; Risk assessment; Toxicokinetics

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; ISOENZYME; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; URIDINE 5' DIPHOSPHO GLUCURONYSYLTRANSFERASE ISOZYME; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; XENOBIOTIC AGENT;

ARTICLE; BIOLOGICAL ACTIVITY; BLOOD LEVEL; CHEMICAL ANALYSIS; CLEARANCE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSIMETRY; ETHNIC GROUP; HEPATIC CLEARANCE; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT TOXICITY TESTING; HUMAN; IN VITRO IN VIVO EXTRAPOLATION; IN VITRO IN VIVO EXTRAPOLATION MODEL; IN VITRO STUDY; INTRINSIC CLEARANCE; METABOLIC CLEARANCE; PHYSIOLOGICAL PROCESS; PLASMA PROTEIN BINDING; POPULATION; POPULATION STRUCTURE; PROTEIN EXPRESSION; RISK ASSESSMENT; STEADY STATE; TOXICITY TESTING; TOXICOKINETICS; AGE; ANIMAL; ANIMAL TESTING ALTERNATIVE; BIOLOGICAL MODEL; DOSE RESPONSE; GENETIC TRANSFECTION; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; SF9 CELL LINE; SPODOPTERA; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMAL USE ALTERNATIVES; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONOSYLTRANSFERASE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOENZYMES; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; RISK ASSESSMENT; SF9 CELLS; SPODOPTERA; TOXICITY TESTS; TRANSFECTION; XENOBIOTICS;

EID: 84922018931     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu169     Document Type: Article

References (90)

1. Andersen, M. E. and Krewski, D. (2009). Toxicity testing in the 21st century: Bringing the vision to life. Toxicol. Sci. 107, 324-330.
2. Besunder, J. B., Reed, M. D. and Blumer, J. L. (1988a). Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin. Pharmacokinet. 14, 189-216.
3. Besunder, J. B., Reed, M. D. and Blumer, J. L. (1988b). Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). Clin. Pharmacokinet. 14, 261-286.
4. Blaauboer, B. J. (2010). Biokinetic modeling and in vitro-in vivo exptrapolations. J. Toxicol. Environ. Health B 13, 242-252.
5. Bramer, S. L., Brisson, J., Corey, A. E. and Mallikaarjun, S. (1999). Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. Clin. Pharmacokinet. 37(Suppl. 2), 69-77.
6. Chauret, N., Gauthier, A. and Nicoll-Griffith, D. A. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 26, 1-4.
7. Cockcroft, D. W. and Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
8. Cohen Hubal, E. A., Richard, A., Aylward, L., Edwards, S., Gallagher, J., Goldsmith, M. R., Isukapalli, S., Tornero-Velez, R., Weber, E. and Kavlock, R. (2010). Advancing exposure characterization for chemical evaluation and risk assessment. J. Toxicol. Environ. Health B Crit. Rev. 13, 299-313.
9. Collins, F. S., Gray, G. M. and Bucher, J. R. (2008). Toxicology. Transforming environmental health protection. Science 319, 906-907.
10. Cresteil, T. (1998). Onset of xenobiotic metabolism in children: Toxicological implications. Food Addit. Contam. 15, 45-51.
11. Crewe, H. K., Barter, Z. E., Yeo, K. R. and Rostami-Hodjegan, A. (2011). Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human livermicrosomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm. Drug Dispos. 32, 303-318.
12. Croom, E. L., Stevens, J.C., Hines, R.N., Wallace, A.D. and Hodgson, E. (2009). Human Hepatic CYP2B6 developmental expression: The impact of age and genotype. Biochem. Pharmacol. 78, 184-190.
13. Dickinson, G. L. and Rostami-Hodjegan, A. (2008). Building virtual human populations: Assessing the propagation of genetic variability in drug metabolism to pharmacokinetics and pharmacodynamics. In Biosimulation in Drug Development (M. Bertau, E. Mosekilde and H. V. Westerhoff Eds.), Wiley-VCH, Weinheim, Germany, pp.425-446.
14. Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R.W. and Kavlock, R. J. (2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95, 5-12.
15. Donato, M. T. and Castell, J. V. (2003). Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: Focus on in vitro studies. Clin. Pharmacokinet. 42, 153-178.
16. Dorne, J. L. (2010). Metabolism, variability and risk assessment. Toxicology 268, 156-164.
17. Dorne, J. L. and Renwick, A. G. (2005). The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 86, 20-26.
18. EPA (2003). A Framework for a Computational Toxicology Research Program in ORD. US Environmental Protection Agency,Washington, DC.
19. EPA (2005). Guidelines for Carcinogen Risk Assessment. US Environmental Protection Agency, Risk Assessment Forum, Washington, DC.
20. EPA (2011). Exposure Factors Handbook: 2011 Edition, EPA/600/R-09/052F. National Center for Environmental Assessment, Washington, DC.
21. Fisher, M. B., Paine, M. F., Strelevitz, T. J. and Wrighton, S. A. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 33, 273-297.
22. Gibson, C. R., Lu, P., Maciolek, C., Wudarski, C., Barter, Z., Rowland-Yeo, K., Stroh, M., Lai, E. and Nicoll-Griffith, D. A. (2013). Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica 43, 1027-1036.
23. Ginsberg, G., Slikker,W., Jr, Bruckner, J. and Sonawane, B. (2004). Incorporating children's toxicokinetics into a risk framework. Environ. Health Perspect. 112, 272-283.
24. Ginsberg, G., Hattis, D., Russ, A. and Sonawane, B. (2005). Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ. Health Perspect. 113, 1243-1249.
25. Ginsberg, G., Hattis, D., Sonawane, B., Russ, A., Banati, P., Kozlak, M., Smolenski, S. and Goble, R. (2002). Evaluation of child/adult pharmacokinetic differences froma database derived from the therapeutic drug literature. Toxicol. Sci. 66, 185-200.
26. Gregory, P. A., Lewinsky, R. H., Gardner-Stephen, D. A. and Mackenzie, P. I. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol. Appl. Pharmacol. 199, 354-363.
27. Hallifax, D., Foster, J. A. and Houston, J. B. (2010). Prediction of human metabolic clearance from in vitro systems: Retrospective analysis and prospective view. Pharm. Res. 27, 2150-2161.
28. Harper, T.W. and Brassil, P. J. (2008). Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J. 10, 200-207.
29. Hattis, D., Ginsberg, G., Sonawane, B., Smolenski, S., Russ, A., Kozlak, M. and Goble, R. (2003).Differences in pharmacokinetics between children and adults-II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal. 23, 117-142.
30. Hines, R. N. (2007). Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol. 21, 169-175.
31. Hiratsuka, M. (2012). In vitro assessment of the allelic variants of cytochrome P450. Drug Metab. Pharmacokinet. 27, 68-84.
32. Hornung, R. W. and Reed, L. D. (1990). Estimation of average concentration in the presence of nondetectable values. Appl. Occup. Environ. Hyg., 5, 46-51.
33. Houck, K. A., Dix, D. J., Judson, R. S., Kavlock, R. J., Yang, J. and Berg, E. L. (2009). Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen. 14, 1054-1066.
34. Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T. and Rostami-Hodjegan, A. (2006). Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36, 473-497.
35. Huang, R., Xia, M., Cho, M. H., Sakamuru, S., Shinn, P., Houck, K. A., Dix, D. J., Judson, R. S.,Witt, K. L., Kavlock, R. J., et al. (2011). Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ. Health Perspect. 119, 1142-1148.
36. IPCS (2005). Chemical-specific adjustment factors for interspecies differences and human variability: Guidance document for use of data in dose/concentration-response assessment. Harmonization Project Document No. 2.World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland.
37. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. and Rostami-Hodjegan, A. (2009). The Simcyp((R)) populationbased ADME simulator. Exp. Opin. Drug Metab. Toxicol., 5, 211-223.
38. Jamroz, R. C., Guerrero, F. D., Pruett, J. H., Oehler, D. D. and Miller, R. J. (2000).Molecular and biochemical survey of acaricide resistance mechanisms in larvae from Mexican strains of the southern cattle tick, Boophilusmicroplus. J. Insect Physiol. 46, 685-695. Johnson, T.N., Rostami-Hodjegan, A. and Tucker, G. T. (2006). Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956.
39. Johnsrud, E. K., Koukouritaki, S.B., Divakaran, K., Brunengraber, L.L., Hines, R.N. and McCarver, D.G. (2003). Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 307, 402-407.
40. Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M., et al. (2010). In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 118, 485-492.
41. Judson, R. S., Kavlock, R. J., Setzer, R.W., Cohen Hubal, E. A., Martin, M. T., Knudsen, T. B., Houck, K. A., Thomas, R. S., Wetmore, B. A. and Dix, D. J. (2011). Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 24, 451-462.
42. Kavlock, R., Ankley, G. T., Collette, T., Francis, E., Hammerstrom, K., Fowle, J., Tilson, H., Toth, G., Schmieder, P., Veith, G. D., et al. (2005). Computational toxicology: Framework, partnerships, and programdevelopment. September 29-30, 2003, Research Triangle Park, North Carolina. Reprod. Toxicol. 19, 265-280.
43. Kavlock, R. J., Austin, C. P. and Tice, R. R. (2009). Toxicity testing in the 21st century: Implications for human health risk assessment. Risk Anal. 29, 485-487; discussion 492-497.
44. Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S. and Kauffman, R. E. (2003). Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167.
45. King, C. D., Rios, G. R., Green, M. D. and Tephly, T. R. (2000). UDP-glucuronosyltransferases. Curr. Drug Metab. 1, 143-161.
46. Knight, A.W., Little, S., Houck, K., Dix, D., Judson, R., Richard, A., McCarroll, N., Akerman, G., Yang, C., Birrell, L., et al. (2009). Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. Regul. Toxicol. Pharmacol. 55, 188-199.
47. Knudsen, T. B.,Houck,K.A., Sipes, N. S., Singh,A.V., Judson, R. S., Martin, M. T., Weissman, A., Kleinstreuer, N. C., Mortensen, H. M., Reif, D. M., et al. (2011). Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets. Toxicology 282, 1-15.
48. Kothare, P. A., Linnebjerg, H., Skrivanek, Z., Reddy, S., Mace, K., Pena, A., Han, J., Fineman, M. and Mitchell, M. (2007). Exenatide effects on statin pharmacokinetics and lipid response. Int. J. Clin. Pharmacol. Ther. 45, 114-120.
49. Koukouritaki, S. B., Manro, J.R., Marsh, S.A., Stevens, J.C., Rettie, A.E., McCarver, D.G. and Hines, R.N. (2004). Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308, 965-974.
50. Leakey, J. E., Hume, R. and Burchell, B. (1987). Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem. J. 243, 859-861.
51. Lipscomb, J. C., Meek,M. E., Krishnan, K., Kedderis, G. L., Clewell, H. and Haber, L. (2004). Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments. Toxicol. Mech. Methods 14, 145-158.
52. Lipscomb, J. C. and Poet, T. S. (2008). In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 118, 82-103.
53. Lock, E. F., Abdo, N., Huang, R., Xia, M., Kosyk, O., O'Shea, S. H., Zhou, Y. H., Sedykh, A., Tropsha, A., Austin, C. P., et al. (2012). Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model. Toxicol. Sci. 126, 578-588.
54. Martin, M. T., Dix, D. J., Judson, R. S., Kavlock, R. J., Reif, D. M., Richard, A. M., Rotroff, D. M., Romanov, S., Medvedev, A., Poltoratskaya, N., et al. (2010). Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem. Res. Toxicol. 23, 578-590.
55. May, D. G., Naukam, R. J., Kambam, J. R. and Branch, R. A. (1992). Cimetidine-carbaryl interaction in humans: Evidence for an active metabolite of carbaryl. J. Pharmacol. Exp. Ther. 262, 1057-1061.
56. McGraw, J. and Waller, D. (2012). Cytochrome P450 variations in different ethnic populations. Expert Opin. Drug Metab. Toxicol. 8, 371-382.
57. Meek,M. E., Renwick, A., Ohanian, E., Dourson, M., Lake, B., Naumann, B. D. and Vu, V. (2002). Guidelines for application of chemical-specific adjustment factors in dose/concentrationresponse assessment. Toxicology 181-182, 115-120.
58. Mignini, F., Tomassoni, D., Streccioni, V., Traini, E. and Amenta, F. (2008). Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. Clin. Exp. Hypertens. 30, 95-108.
59. Mihara, K., Suzuki, A., Kondo, T., Yasui, N., Furukori, H., Nagashima, U., Otani, K., Kaneko, S. and Inoue, Y. (1999). Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin. Pharmacol. Ther. 65, 291-294.
60. Miyagi, S. J. and Collier, A. C. (2007). Pediatric development of glucuronidation: The ontogeny of hepatic UGT1A4. Drug Metab. Dispos. 35, 1587-1592.
61. NRC (1983). Risk Assessment in the Federal Government: Managing the Process. National Academy Press, Washington, DC.
62. NRC (1993). Pesticides in the Diets of Infants and Children. National Research Council of the National Academies, Washington, DC.
63. NRC (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academy Press, Washington, DC.
64. NRC (2009). Science and Decisions: Advancing Risk Assessment. National Academies Press. Washington, DC.
65. Pinto, N. and Dolan, M. E. (2011). Clinically relevant genetic variations in drug metabolizing enzymes. Curr. Drug Metab. 12, 487-497.
66. Proctor, N. J., Tucker, G. T. and Rostami-Hodjegan, A. (2004). Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors. Xenobiotica 34, 151-178.
67. Renwick, A. G. (1998). Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit. Contam. 15(Suppl. 1), 17-35.
68. Renwick, A. G. and Lazarus, N. R. (1998). Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27, 3-20.
69. Ritter, J. K. (2007). Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin. Drug Metab. Toxicol. 3, 93-107.
70. Rotroff, D. M., Beam, A. L., Dix, D. J., Farmer, A., Freeman, K. M., Houck, K. A., Judson, R. S., LeCluyse, E. L., Martin, M. T., Reif, D. M., et al. (2010a). Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J. Toxicol. Environ. Health B Crit. Rev. 13, 329-346.
71. Rotroff, D. M.,Wetmore, B. A., Dix, D. J., Ferguson, S. S., Clewell, H. J., Houck, K. A., Lecluyse, E. L., Andersen, M. E., Judson, R. S., Smith, C. M., et al. (2010b). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 117, 348-358.
72. Rowland-Yeo, K., Rostami-Hodjegan, A. and Tucker, G.T. (2003). Abundance of cytochrome P450 in human liver: A meta analysis. Br. J. Clin. Pharmacol. 57, 687-688.
73. Rubin, M., Bruck, E and Rapoport, M (1949). Maturation of renal function in childhood: Clearance studies. J. Clin. Invest. 28, 1144-1162.
74. Salem, F., Rostami-Hodjegan, A. and Johnson, T. N. (2013). Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature. J. Clin. Pharmacol. 53, 559-566.
75. Schmucker, D. L. (2005). Age-related changes in liver structure and function: Implications for disease ? Exp. Gerontol. 40, 650-659.
76. Singh, D., Kashyap, A., Pandey, R. V. and Saini, K. S. (2011). Novel advances in cytochrome P450 research. Drug Discov. Today 16, 793-799.
77. Stringer, R. A., Strain-Damerell, C., Nicklin, P. and Houston, J. B. (2009). Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab. Dispos. 37, 1025-1034.
78. Suzuki, A., Yasui-Furukori, N., Mihara, K., Kondo, T., Furukori, H., Inoue, Y., Kaneko, S. and Otani, K. (2003). Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther. Drug Monit. 25, 192-196
79. Tanaka, E. (1998). In vivo age-related changes in hepatic drugoxidizing capacity in humans. J. Clin. Pharm. Ther. 23, 247-255.
80. Tan, Y. M., Liao, K. H. and Clewell, H. J., 3rd (2007). Reverse dosimetry: Interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expo. Sci. Environ. Epidemiol. 17, 591-603.
81. Thelen, K. and Dressman, J. B. (2009). Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol. 61, 541-558.
82. Tukey, J. W. (1977). Exploratory Data Analysis. Addison-Wesley. ReadingMA.
83. Tukey, R. H. and Strassburg, C. P. (2000). Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616.
84. USEPA (2007). Reregistration Eligibility Decision for Carbaryl. US Environmental Protection Agency, Washington, DC.
85. Venkatakrishnan, K., von Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L. and Greenblatt, D. J. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28, 1493-1504.
86. Wetmore, B. A. (2014). Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Toxicology doi: 10.1016/j.tox.2014.05.012. [Epub ahead of print]
87. Wetmore, B. A.,Wambaugh, J. F., Ferguson, S. S., Sochaski, M. A., Rotroff, D. M., Freeman, K., Clewell, H. J., III, Dix, D. J., Andersen, M. E., Houck, K. A., et al. (2012). Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 125, 157-174.
88. Whyard, S., Russell, R. J. and Walker, V. K. (1994). Insecticide resistance and malathion carboxylesterase in the sheep blowfly, Lucilia cuprina. Biochem. Genet. 32, 9-24.
89. Yasui-Furukori, N., Kondo, T., Mihara, K., Suzuki, A., Inoue, Y., De Vries, R. and Kaneko, S. (2002). Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J. Clin. Pharmacol. 42, 1083-1088.
90. Yokoi, T. (2009). Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J. Toxicol. Sci. 34(Suppl. 2), SP307-SP312.